Advertisement Philogen expands research and development agreement with AbbVie - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Philogen expands research and development agreement with AbbVie

Philogen has entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.

Philogen CEO Duccio Neri said: "We are excited to expand our collaboration with AbbVie, a leader in the field of antibody therapeutics.

"The first agreement between the companies focused on osteoarthritis, and we are continuing to explore the shared scientific strengths of both companies.”

No financial details of the agreement were released.